Cumberland Pharmaceuticals Inc., of Nashville, Tenn., reported top-line results from a pediatric study showing that Caldolor (ibuprofen) injection was associated with a statistically significant reduction in the number of postoperative narcotic doses required in tonsillectomy patients ranging in age from 6 to 16
ADX71149 also is being studied in a Phase II trial in positive and negative symptoms of schizophrenia, with top-line data expected in the fourth quarter
In April, Biodel reported positive top-line results from a Phase I study of BIOD-123, demonstrating the formulation had more rapid absorption than Humalog (insulin lispro, Eli Lilly and Co.), with comparable injection-site tolerability...The company expects to report top-line safety and efficacy data in the third quarter of 2013
The company expects to report top-line data in early 2013...Separately, InSite Vision disclosed top-line data from a preclinical pharmacokinetic comparative study of DuraSite and DuraSite 2, its next-generation drug delivery system for ophthalmic therapeutics
Palatin Technologies Inc., of Cranbury, N.J., said the last patient completed treatment in its Phase IIb study testing melanocortin agonist bremelanotide in female sexual dysfunction, and top-line data are expected in the first half of next quarter
Top-line results from the REFINE (Randomized, Double-blind Evaluation of Submental Fat Reduction IN ATX-101 TrEated Patients)-1 and REFINE-2 trials are expected in mid-2013...Top-line data for both studies is expected late in the second half of 2013
Rexahn Pharmaceuticals Inc., of Rockville, Md., said top-line results from a Phase II trial showed that Archexin in combination with gemcitabine provided a median survival of 9
Previously reported top-line results showed that the primary endpoints of improvement from baseline in curvature deformity compared to placebo and change from baseline in the bother domain compared to placebo were both met
Evolva Holdings SA, of Reinach, Switzerland, said top-line results for the first 32 patients enrolled in the Phase IIa study testing EV-077, a reversible antagonist of isoprostanes and prostanoids, showed promising efficacy, indicating that the drug, when given orally twice daily to patients with Type II diabetes, provided antiplatelet activity, reduced exercise-induced proteinuria and increased forearm blood flow
The company also reported top-line results from its Phase I study of LX7101, an inhibitor of LIM domain kinase 2 (LIMK2), in glaucoma...The companies reported top-line data from AFFIRM last year. (See BioWorld Today, Nov. 4, 2011
Pfizer Inc., of New York, reported top-line results from the Phase III ORAL Start study of JAK inhibitor tofacitinib in moderate to severe active rheumatoid arthritis (RA
Novavax Inc., of Rockville, Md., reported positive top-line results from a Phase II trial of its seasonal influenza virus-like particle (VLP) candidate showing that the product had immunogenicity against all four viral strains, and was well tolerated with no vaccine-related serious adverse events
Pfizer Inc., of New York, reported top-line data showing that Lyrica (pregabalin) resulted in low discontinuation symptoms after tapering treatment following three months and six months in generalized anxiety disorder patients...In separate news, Pfizer reported top-line data showing that Lyrica does not affect the reproductive function in healthy males when compared to placebo
Anthera reported top-line data from the PEARL-SC study late last month, showing that the trial missed its primary endpoint, defined as clinical improvement at 24 weeks in the SLE responder index for the pooled blisibimod dose groups
Top-line data from both studies were reported last year